NL8120190A - - Google Patents
Download PDFInfo
- Publication number
- NL8120190A NL8120190A NL8120190A NL8120190A NL8120190A NL 8120190 A NL8120190 A NL 8120190A NL 8120190 A NL8120190 A NL 8120190A NL 8120190 A NL8120190 A NL 8120190A NL 8120190 A NL8120190 A NL 8120190A
- Authority
- NL
- Netherlands
- Prior art keywords
- msh
- peptides
- acth
- rats
- behavior
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 27
- GZWUQPQBOGLSIM-VOOUCTBASA-N γ msh Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C(C)C)C1=CC=C(O)C=C1 GZWUQPQBOGLSIM-VOOUCTBASA-N 0.000 description 21
- 102400000744 Melanotropin gamma Human genes 0.000 description 20
- 101800000520 Melanotropin gamma Proteins 0.000 description 20
- 241000700159 Rattus Species 0.000 description 19
- 239000000902 placebo Substances 0.000 description 14
- 229940068196 placebo Drugs 0.000 description 14
- 108010091893 Cosyntropin Proteins 0.000 description 10
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000024703 flight behavior Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 101800005049 Beta-endorphin Proteins 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 102400000748 Beta-endorphin Human genes 0.000 description 6
- 101800000414 Corticotropin Proteins 0.000 description 6
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 6
- 101710200814 Melanotropin alpha Proteins 0.000 description 6
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 6
- 230000008033 biological extinction Effects 0.000 description 6
- 230000009194 climbing Effects 0.000 description 6
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 6
- 229960004127 naloxone Drugs 0.000 description 6
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 6
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 5
- 229960000258 corticotropin Drugs 0.000 description 5
- -1 2-methylpropionyl Chemical group 0.000 description 4
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 108010042362 beta-Lipotropin Proteins 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
- 102400000742 Lipotropin beta Human genes 0.000 description 3
- 102400000747 Melanocyte-stimulating hormone beta Human genes 0.000 description 3
- 101710129905 Melanotropin beta Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229960002069 diamorphine Drugs 0.000 description 3
- SFVVQRJOGUKCEG-OPQSFPLASA-N β-MSH Chemical compound C1C[C@@H](O)[C@H]2C(COC(=O)[C@@](O)([C@@H](C)O)C(C)C)=CCN21 SFVVQRJOGUKCEG-OPQSFPLASA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000003370 grooming effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 2
- 229960003086 naltrexone Drugs 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000003401 opiate antagonist Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- HAAUASBAIUJHAN-LXOXETEGSA-N (4s)-4-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-(carboxymethylamino)-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol- Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 HAAUASBAIUJHAN-LXOXETEGSA-N 0.000 description 1
- 108010040117 ACTH (1-10) Proteins 0.000 description 1
- 108010068681 ACTH (4-10) Proteins 0.000 description 1
- 102000008064 Corticotropin Receptors Human genes 0.000 description 1
- 108010074311 Corticotropin Receptors Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 102400000746 Lipotropin gamma Human genes 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000009227 behaviour therapy Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 108010075816 gamma-Lipotropin Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000021061 grooming behavior Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910000000 metal hydroxide Inorganic materials 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000000945 opiatelike Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/695—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3023813A DE3023813A1 (de) | 1980-06-25 | 1980-06-25 | Arzneimittel |
| DE3023813 | 1980-06-25 | ||
| EP8100075 | 1981-06-15 | ||
| PCT/EP1981/000075 WO1982000031A1 (en) | 1980-06-25 | 1981-06-15 | Biologically active peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8120190A true NL8120190A (enExample) | 1982-05-03 |
Family
ID=6105445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8120190A NL8120190A (enExample) | 1980-06-25 | 1981-06-15 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4410511A (enExample) |
| JP (1) | JPS57500829A (enExample) |
| AU (1) | AU542296B2 (enExample) |
| BE (1) | BE889384A (enExample) |
| CA (1) | CA1147654A (enExample) |
| CH (1) | CH647410A5 (enExample) |
| DE (1) | DE3023813A1 (enExample) |
| FR (1) | FR2485374A1 (enExample) |
| GB (1) | GB2086396B (enExample) |
| IT (1) | IT1144816B (enExample) |
| NL (1) | NL8120190A (enExample) |
| SE (1) | SE8200757L (enExample) |
| WO (1) | WO1982000031A1 (enExample) |
| ZA (1) | ZA814055B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146113A3 (de) * | 1983-12-15 | 1987-08-19 | Dieter Aderhold | Wirkstoff und therapeutisches Mittel zur Behandlung von Fehlfunktionen des Diencephalon, von Nervenerkrankungen und Erkrankungen der Haut |
| DE3345358A1 (de) * | 1983-12-15 | 1985-06-27 | Dieter Prof. Dr. Dr. 5883 Kierspe Aderhold | Therapeutisches mittel zur behandlung von fehlfunktionen des menschlichen diencephalon und/oder der hypophyse, insbesondere der multiplen sklerose |
| IT1218472B (it) * | 1985-08-30 | 1990-04-19 | Alfio Bertolini | Composizioni farmaceutiche comprendenti acht (1-24) per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria |
| US4844895A (en) * | 1985-11-01 | 1989-07-04 | New York University | Composition containing a peptide fragment of platelet factor four and method for restoring suppressed immune responses |
| GB2269821B (en) * | 1992-08-08 | 1996-06-05 | Shanghai Inst Biochemistry | Memory enhancing peptides and pharmaceutical compositions containing them |
| CA2986423C (en) | 2015-05-18 | 2022-05-10 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Enhanced melanoma cancer prevention by novel melanotropins |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130980C (enExample) * | 1960-06-03 | 1900-01-01 | ||
| FR1405270A (fr) * | 1963-05-20 | 1965-07-09 | Ciba Geigy | Procédé de préparation d'un polypeptide, à savoir de la beta-msh |
| CH523227A (de) * | 1966-12-30 | 1972-05-31 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Peptidamide mit ACTH-Wirkung |
-
1980
- 1980-06-25 DE DE3023813A patent/DE3023813A1/de not_active Withdrawn
-
1981
- 1981-06-15 NL NL8120190A patent/NL8120190A/nl unknown
- 1981-06-15 CH CH1218/82A patent/CH647410A5/de not_active IP Right Cessation
- 1981-06-15 JP JP56501930A patent/JPS57500829A/ja active Pending
- 1981-06-15 AU AU72268/81A patent/AU542296B2/en not_active Expired - Fee Related
- 1981-06-15 GB GB8201463A patent/GB2086396B/en not_active Expired
- 1981-06-15 WO PCT/EP1981/000075 patent/WO1982000031A1/en not_active Ceased
- 1981-06-16 ZA ZA814055A patent/ZA814055B/xx unknown
- 1981-06-18 US US06/275,049 patent/US4410511A/en not_active Expired - Fee Related
- 1981-06-22 FR FR8112213A patent/FR2485374A1/fr active Granted
- 1981-06-24 CA CA000380521A patent/CA1147654A/en not_active Expired
- 1981-06-24 IT IT67878/81A patent/IT1144816B/it active
- 1981-06-25 BE BE0/205213A patent/BE889384A/fr not_active IP Right Cessation
-
1982
- 1982-02-10 SE SE8200757A patent/SE8200757L/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2485374A1 (fr) | 1981-12-31 |
| CA1147654A (en) | 1983-06-07 |
| JPS57500829A (enExample) | 1982-05-13 |
| IT8167878A0 (it) | 1981-06-24 |
| GB2086396B (en) | 1983-10-12 |
| FR2485374B1 (enExample) | 1984-11-30 |
| WO1982000031A1 (en) | 1982-01-07 |
| GB2086396A (en) | 1982-05-12 |
| AU542296B2 (en) | 1985-02-14 |
| IT1144816B (it) | 1986-10-29 |
| BE889384A (fr) | 1981-12-28 |
| DE3023813A1 (de) | 1982-01-21 |
| AU7226881A (en) | 1982-01-19 |
| US4410511A (en) | 1983-10-18 |
| CH647410A5 (de) | 1985-01-31 |
| ZA814055B (en) | 1982-07-28 |
| SE8200757L (sv) | 1982-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Del Pozo et al. | Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration | |
| Malin et al. | FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat | |
| Itoh et al. | Caerulein and cholecystokinin suppress β-endorphin-induced analgesia in the rat | |
| Dyer et al. | Fasting impairs LH secretion in female rats by activating an inhibitory opioid pathway | |
| AU2001283938A1 (en) | Ghrelin antagonists | |
| Yamazaki et al. | The opioid peptide analogue biphalin induces less physical dependence than morphine | |
| van Ree et al. | Behavioral profile of ψ-MSH: Relationship with acta and β-endorphin action | |
| US4261885A (en) | Novel somatostatin analogue | |
| Copp et al. | New peripheral antagonists of 5-hydroxytryptamine | |
| DE1543796A1 (de) | Verfahren zur Herstellung biologisch aktiver Peptide | |
| NL8120190A (enExample) | ||
| Janković et al. | Enkephalins and anaphylactic shock: Modulation and prevention of shock in the rat | |
| Mantle | Interruption of early pregnancy in mice by oral administration of agroclavine and sclerotia of Claviceps fusiformis (Loveless) | |
| Graf et al. | Effects of repeated DSIP and DSIP-P administration on the circadian locomotor activity of rats | |
| Kastin et al. | Naloxone-like actions of MIF-1 do not require the presence of the pituitary | |
| O'Donohue et al. | Comparison of biological and behavioral activities of alpha-and gamma-melanocyte stimulating hormones | |
| US4256736A (en) | Psychopharmacological peptides | |
| Lloyd et al. | Cholinergic neuromuscular synapses in Aplysia have low endogenous acetylcholinesterase activity and a high-affinity uptake system for acetylcholine | |
| Hemmer et al. | Effects of naloxone and its quaternary form on fluid consumption in rats | |
| Pedersen et al. | Gamma3-melanotropin promotes mitochondrial cholesterol accumulation in the rat adrenal cortex | |
| Locatelli et al. | Prolactin and growth hormone releasing activity of [D-Met2, Pro5]-enkephalinamide in the rat after systemic administration | |
| Gabriel et al. | Effects of a sustained-release naloxone pellet on luteinizing hormone secretion in female rats | |
| EP0099057B1 (de) | N-Acylderivate von Peptiden, ihre Herstellung und Verwendung bei der Bekämpfung von Krankheiten und Mittel dafür | |
| De Wied | Behavioural effects of neuropeptides related to ß-LPH | |
| Bodycote et al. | Naloxone-induced contracture of ileum from stressed guinea pigs |